- Huidige behandelopties
EMA: "The main treatment was chemotherapy (medicines to treat cancer) usually in combination with medicines called monoclonal antibodies and sometimes with radiotherapy (treatment with radiation). Autologous haematopoietic (blood) stem-cell transplantation was also used in patients at risk of the disease coming back after treatment. This procedure involves replacing the patient's bone marrow with the patient's own stem cells to form new bone marrow that produces healthy blood cells."
- Therapeutische waarde
EMA: "the sponsor has provided sufficient information to show that the medicine might be of significant benefit for patients with diffuse large B-cell lymphoma because early results suggest that adding polatuzumab vedotin to existing treatments improved their effectiveness in patients whose disease had come back or in whom other treatment had not worked well enough."
Fabrikant: "Verbeterde PFS en OS ten opzichte van bendamustine+rituximab".
1 maal per 3 weken
- Dosering per toediening
NCT03274492,Sehn et al 2018 Studie: GO29365